Alphatec Holdings Inc (NASDAQ:ATEC) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $4.00 for the company and are predicting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also given Alphatec an industry rank of 151 out of 256 based on the ratings given to its competitors.

A number of research analysts have commented on ATEC shares. Zacks Investment Research upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Monday. HC Wainwright set a $4.00 price objective on shares of Alphatec and gave the company a “buy” rating in a research note on Tuesday, February 26th.

ATEC traded up $0.22 during trading hours on Wednesday, reaching $4.70. 17,409 shares of the stock traded hands, compared to its average volume of 333,764. The firm has a market cap of $193.05 million, a price-to-earnings ratio of -8.05 and a beta of 1.52. Alphatec has a fifty-two week low of $1.18 and a fifty-two week high of $4.49. The company has a current ratio of 2.31, a quick ratio of 1.53 and a debt-to-equity ratio of 4.79.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Thursday, May 9th. The medical technology company reported ($0.20) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.20). The business had revenue of $24.56 million during the quarter, compared to analyst estimates of $24.00 million. Alphatec had a negative net margin of 42.16% and a negative return on equity of 156.32%. On average, analysts forecast that Alphatec will post -0.62 earnings per share for the current fiscal year.

In other Alphatec news, EVP Kelli Mari Howell purchased 100,000 shares of Alphatec stock in a transaction dated Monday, March 11th. The shares were bought at an average cost of $2.59 per share, for a total transaction of $259,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Craig E. Hunsaker sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $4.00, for a total transaction of $200,000.00. Following the completion of the transaction, the executive vice president now owns 626,014 shares in the company, valued at $2,504,056. The disclosure for this sale can be found here. Company insiders own 44.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Beacon Pointe Wealth Advisors LLC bought a new position in shares of Alphatec in the fourth quarter worth $36,000. Suntrust Banks Inc. bought a new stake in Alphatec in the fourth quarter worth approximately $58,000. Raymond James Financial Services Advisors Inc. increased its holdings in Alphatec by 49.2% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 29,063 shares of the medical technology company’s stock worth $67,000 after purchasing an additional 9,579 shares in the last quarter. Royce & Associates LP increased its holdings in Alphatec by 124.8% in the fourth quarter. Royce & Associates LP now owns 35,000 shares of the medical technology company’s stock worth $80,000 after purchasing an additional 19,432 shares in the last quarter. Finally, Fifth Third Bancorp bought a new stake in Alphatec in the first quarter worth approximately $121,000. Institutional investors own 18.04% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

Recommended Story: Different Options Trading Strategies

Get a free copy of the Zacks research report on Alphatec (ATEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.